Vivek Subbiah

31.1k total citations · 9 hit papers
599 papers, 12.2k citations indexed

About

Vivek Subbiah is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Vivek Subbiah has authored 599 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 318 papers in Oncology, 257 papers in Pulmonary and Respiratory Medicine and 185 papers in Cancer Research. Recurrent topics in Vivek Subbiah's work include Cancer Genomics and Diagnostics (157 papers), Lung Cancer Treatments and Mutations (138 papers) and Cancer Immunotherapy and Biomarkers (78 papers). Vivek Subbiah is often cited by papers focused on Cancer Genomics and Diagnostics (157 papers), Lung Cancer Treatments and Mutations (138 papers) and Cancer Immunotherapy and Biomarkers (78 papers). Vivek Subbiah collaborates with scholars based in United States, France and Germany. Vivek Subbiah's co-authors include Razelle Kurzrock, Funda Meric‐Bernstam, David S. Hong, Filip Jankú, Aung Naing, Siqing Fu, Maria E. Cabanillas, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou and Mohamed A. Gouda and has published in prestigious journals such as Cell, Nature Medicine and Nature Communications.

In The Last Decade

Vivek Subbiah

554 papers receiving 12.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

2017 607 citations Vivek Subbiah, Maria E. Cabanillas et al. profile →
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

2020 314 citations Vivek Subbiah, Milind Javle et al. profile →
The next generation of evidence-based medicine

2023 269 citations Vivek Subbiah profile →
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

2022 244 citations Vivek Subbiah, Alexander Drilon et al. profile →
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

2021 196 citations Vivek Subbiah et al. profile →
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

2022 183 citations Vivek Subbiah, Maria E. Cabanillas et al. Annals of Oncology profile →
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

2022 144 citations Vivek Subbiah, Philippe A. Cassier et al. profile →
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

2022 119 citations Alexander Drilon, Vivek Subbiah et al. profile →
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

2023 105 citations Vivek Subbiah, Solange Peters et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vivek Subbiah United States	54	6.0k	4.6k	3.7k	3.1k	1.7k	599	12.2k
Aung Naing United States	58	5.8k 1.0×	3.0k 0.6×	4.4k 1.2×	3.0k 1.0×	1.4k 0.8×	483	12.5k
Bhumsuk Keam South Korea	50	6.1k 1.0×	4.0k 0.9×	2.1k 0.6×	1.6k 0.5×	981 0.6×	373	9.9k
Ezra E.W. Cohen United States	67	8.5k 1.4×	5.6k 1.2×	4.7k 1.3×	2.0k 0.6×	895 0.5×	421	16.9k
Patrick Schöffski Belgium	68	9.6k 1.6×	9.5k 2.1×	4.8k 1.3×	2.2k 0.7×	1.9k 1.1×	510	19.4k
Roger B. Cohen United States	56	9.2k 1.5×	5.9k 1.3×	5.4k 1.5×	1.9k 0.6×	1.2k 0.7×	328	17.5k
Sabino De Placido Italy	64	7.8k 1.3×	4.5k 1.0×	4.4k 1.2×	3.7k 1.2×	1.0k 0.6×	381	14.0k
Julian R. Molina United States	44	10.5k 1.8×	8.2k 1.8×	6.2k 1.7×	3.3k 1.0×	1.1k 0.6×	216	18.3k
David Olmos United Kingdom	48	4.1k 0.7×	6.3k 1.4×	3.2k 0.9×	3.2k 1.0×	711 0.4×	233	10.4k
Heather A. Wakelee United States	60	6.9k 1.1×	7.5k 1.6×	3.9k 1.1×	4.0k 1.3×	1.2k 0.7×	447	13.5k
Lisa Licitra Italy	63	8.1k 1.3×	4.3k 0.9×	3.1k 0.8×	1.4k 0.5×	1.1k 0.6×	447	16.0k

Countries citing papers authored by Vivek Subbiah

Since Specialization

Citations

This map shows the geographic impact of Vivek Subbiah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek Subbiah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek Subbiah more than expected).

Fields of papers citing papers by Vivek Subbiah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivek Subbiah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek Subbiah. The network helps show where Vivek Subbiah may publish in the future.

Co-authorship network of co-authors of Vivek Subbiah

This figure shows the co-authorship network connecting the top 25 collaborators of Vivek Subbiah. A scholar is included among the top collaborators of Vivek Subbiah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivek Subbiah. Vivek Subbiah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Monk, Bradley J., Manish R. Patel, Sarper Toker, Vivek Subbiah, & Lucio Gordan. (2025). Development of anti-cancer medicines in the current era. Cancer Treatment and Research Communications. 45. 101002–101002.

Desai, Aakash, et al.. (2024). Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?. Cancers. 16(22). 3753–3753. 2 indexed citations

Denu, Ryan A., Justin T. Moyers, Mohamed A. Gouda, et al.. (2023). The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications. Clinical Cancer Research. 29(22). 4669–4678. 4 indexed citations

Son, Ji, Heather Lin, Siqing Fu, et al.. (2023). Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. SHILAP Revista de lepidopterología. 6(1). 10–18. 1 indexed citations

Wirth, Lori J., Vivek Subbiah, Francis P. Worden, et al.. (2023). 2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001. Annals of Oncology. 34. S1147–S1148. 3 indexed citations

Narayanan, Santhosshi, Felippe Lazar Neto, Kimberson Tanco, et al.. (2020). Cannabidiol (CBD) Oil, Cancer, and Symptom Management: A Google Trends Analysis of Public Interest. The Journal of Alternative and Complementary Medicine. 26(4). 346–348. 7 indexed citations

Kurzrock, Razelle, Douglas W. Ball, Marianna Zahurak, et al.. (2019). A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clinical Cancer Research. 25(18). 5475–5484. 19 indexed citations

Subbiah, Vivek, Pete Anderson, Kalevi Kairemo, et al.. (2019). Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research. 25(13). 3802–3810. 32 indexed citations

Rich, Thereasa A., Karen L. Reckamp, Young Kwang Chae, et al.. (2019). Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clinical Cancer Research. 25(19). 5832–5842. 68 indexed citations

10.

Hess, Kenneth R., Filip Jankú, Nora Sánchez, et al.. (2019). Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research. 26(8). 1924–1931. 40 indexed citations

11.

Subbiah, Vivek, Ravi Murthy, David S. Hong, et al.. (2018). Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clinical Cancer Research. 24(16). 3845–3856. 29 indexed citations

12.

Subbiah, Vivek, Salah-Eddine Lamhamedi-Cherradi, Branko Cuglievan, et al.. (2018). Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clinical Cancer Research. 24(19). 4865–4873. 61 indexed citations

13.

Kehl, Kenneth L., Siqing Fu, Goldy C. George, et al.. (2017). Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clinical Cancer Research. 23(15). 4155–4162. 4 indexed citations

14.

Subbiah, Vivek, Juneko E. Grilley‐Olson, Austin J. Combest, et al.. (2017). Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. 24(1). 43–51. 82 indexed citations

15.

Tang, Chad, James W. Welsh, Patricia M. de Groot, et al.. (2016). Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research. 23(6). 1388–1396. 251 indexed citations

16.

Wheler, Jennifer J., Filip Jankú, Aung Naing, et al.. (2016). TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics. 15(10). 2475–2485. 73 indexed citations

17.

Kato, Shumei, Vivek Subbiah, Erica Marchlik, et al.. (2016). RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clinical Cancer Research. 23(8). 1988–1997. 201 indexed citations

18.

Wheler, Jennifer J., Filip Jankú, Aung Naing, et al.. (2016). Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research. 76(13). 3690–3701. 149 indexed citations

19.

Goswami, Rashmi S., Keyur P. Patel, Rajesh R. Singh, et al.. (2015). Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research. 21(11). 2644–2651. 59 indexed citations

20.

Tang, Chad, Kenneth R. Hess, Denis L. Jardim, et al.. (2014). Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. Clinical Cancer Research. 20(23). 5956–5963. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact